Search

AstraZeneca PLC

Closed

Sector Healthcare

10,052 0.52

Overview

Share price change

24h

Current

Min

9873

Max

10056

Key metrics

By Trading Economics

Income

-498M

1.4B

Sales

632M

14B

P/E

Sector Avg

38.58

94.998

EPS

2.08

Dividend yield

2.016

Profit margin

10.531

EBITDA

548M

4.7B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+34.13 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.02%

2.40%

Next Earnings

٦ فبراير ٢٠٢٥

Market Stats

By TradingEconomics

Market Cap

-17B

155B

Previous open

10051.48

Previous close

10052

News Sentiment

By Acuity

40%

60%

154 / 392 Ranking in Healthcare

AstraZeneca PLC Chart

Past performance is not a reliable indicator of future results.

Related News

١٢ نوفمبر ٢٠٢٤، ٠٧:٥٥ م UTC

Earnings

AstraZeneca Expands U.S. Investment Plan -- 3rd Update

١٢ نوفمبر ٢٠٢٤، ١١:٠٢ ص UTC

Earnings

AstraZeneca Raises Outlook, Plans U.S. Investment -- Update

١٢ نوفمبر ٢٠٢٤، ٠٧:٣٧ ص UTC

Earnings

AstraZeneca Raises Outlook on Earnings, Sales Beat

١٠ سبتمبر ٢٠٢٤، ٠٩:٢٩ ص UTC

Major Market Movers

AstraZeneca Shares Slump After Cancer Drug Misses Key Target

١٨ نوفمبر ٢٠٢٤، ١٠:٣٣ ص UTC

Market Talk

Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk

١٥ نوفمبر ٢٠٢٤، ٠١:٠٨ م UTC

Top News

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

١٥ نوفمبر ٢٠٢٤، ١٠:٢٩ ص UTC

Hot Stocks

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

١٢ نوفمبر ٢٠٢٤، ٠٣:٣٠ م UTC

Top News

AstraZeneca Expands U.S. Investment Plan -- 2nd Update

١٢ نوفمبر ٢٠٢٤، ٠١:٣٩ م UTC

Market Talk

AstraZeneca's Results Make $80B Revenue Target Look Achievable -- Market Talk

١٢ نوفمبر ٢٠٢٤، ١٠:٤٩ ص UTC

Market Talk
Earnings

AstraZeneca Seen With Positive Momentum at Pivotal Period -- Market Talk

١٢ نوفمبر ٢٠٢٤، ٠٩:٥٢ ص UTC

Market Talk

AstraZeneca's New Guidance Could Imply Consensus Upgrades -- Market Talk

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC

Earnings

AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC

Earnings

AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC

Earnings

AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC

Earnings

AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC

Earnings

AstraZeneca Raises 2024 View

١٢ نوفمبر ٢٠٢٤، ٠٧:٠١ ص UTC

Earnings

Analysts Saw AstraZeneca 3Q Sales at $13.1B

١٢ نوفمبر ٢٠٢٤، ٠٧:٠١ ص UTC

Earnings

Analysts Saw AstraZeneca 3Q Core EPS at $2.04

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٠ ص UTC

Earnings

AstraZeneca PLC 3Q EPS 91c

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٠ ص UTC

Earnings

AstraZeneca PLC 3Q Net Pft $1.43B

١٢ نوفمبر ٢٠٢٤، ٠٧:٠٠ ص UTC

Earnings

AstraZeneca PLC 3Q Oper Pft $2.11B

٧ نوفمبر ٢٠٢٤، ٠٨:٠٣ ص UTC

Top News

China Has Detained a Senior AstraZeneca Executive -- Update

٦ نوفمبر ٢٠٢٤، ٠٦:٥٥ م UTC

Top News

China Has Detained Senior AstraZeneca Executive -- WSJ

١ نوفمبر ٢٠٢٤، ٠٣:٠٠ ص UTC

Top News

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

٣١ أكتوبر ٢٠٢٤، ٠٧:٤٨ م UTC

Top News

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update

٣١ أكتوبر ٢٠٢٤، ٠٢:٤٣ م UTC

Top News

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- WSJ

١٢ سبتمبر ٢٠٢٤، ٠٥:٠١ م UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

١٢ سبتمبر ٢٠٢٤، ١١:٠٠ ص UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

١٠ سبتمبر ٢٠٢٤، ٠١:٠٨ م UTC

Market Talk

AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk

٩ سبتمبر ٢٠٢٤، ٠٧:٥٦ ص UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

AstraZeneca PLC Forecast

Price Target

By TipRanks

34.13% upside

12 Months Forecast

Average 13,371.56 GBX  34.13%

High 18,000 GBX

Low 10,500 GBX

Based on 15 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

9

Buy

5

Hold

1

Sell

Sentiment

By Acuity

154 / 392 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.